Treatment of anemia in renal transplantation: impact of a stricter application of hemoglobin targets.
Identifieur interne : 000211 ( Main/Exploration ); précédent : 000210; suivant : 000212Treatment of anemia in renal transplantation: impact of a stricter application of hemoglobin targets.
Auteurs : M A Gentil [Espagne] ; M A Pérez-Valdivia ; F M González-Roncero ; M. L Pez-Mendoza ; V. Cabello ; G. Bernal ; M. Su Er ; P. PereiraSource :
- Transplantation proceedings [ 0041-1345 ] ; 2008.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Anémie (sang), Anémie (traitement médicamenteux), Anémie (épidémiologie), Calendrier d'administration des médicaments (MeSH), Complications postopératoires (thérapie), Créatinine (métabolisme), Défaillance rénale chronique (chirurgie), Défaillance rénale chronique (complications), Facteurs de risque (MeSH), Femelle (MeSH), Humains (MeSH), Hémoglobines (métabolisme), Immunosuppresseurs (usage thérapeutique), Inhibiteurs de l'enzyme de conversion de l'angiotensine (usage thérapeutique), Maladies cardiovasculaires (épidémiologie), Mâle (MeSH), Transplantation rénale (effets indésirables), Transplantation rénale (immunologie), Transplantation rénale (physiologie), Érythropoïétine (usage thérapeutique), Études rétrospectives (MeSH).
- MESH :
- chirurgie : Défaillance rénale chronique.
- effets indésirables : Défaillance rénale chronique, Transplantation rénale.
- immunologie : Transplantation rénale.
- métabolisme : Créatinine, Hémoglobines.
- physiologie : Transplantation rénale.
- sang : Anémie.
- thérapie : Complications postopératoires.
- traitement médicamenteux : Anémie.
- usage thérapeutique : Immunosuppresseurs, Inhibiteurs de l'enzyme de conversion de l'angiotensine, Érythropoïétine.
- épidémiologie : Anémie, Maladies cardiovasculaires.
- Adulte, Adulte d'âge moyen, Calendrier d'administration des médicaments, Facteurs de risque, Femelle, Humains, Mâle, Études rétrospectives.
English descriptors
- KwdEn :
- Adult (MeSH), Anemia (blood), Anemia (drug therapy), Anemia (epidemiology), Angiotensin-Converting Enzyme Inhibitors (therapeutic use), Cardiovascular Diseases (epidemiology), Creatinine (metabolism), Drug Administration Schedule (MeSH), Erythropoietin (therapeutic use), Female (MeSH), Hemoglobins (metabolism), Humans (MeSH), Immunosuppressive Agents (therapeutic use), Kidney Failure, Chronic (complications), Kidney Failure, Chronic (surgery), Kidney Transplantation (adverse effects), Kidney Transplantation (immunology), Kidney Transplantation (physiology), Male (MeSH), Middle Aged (MeSH), Postoperative Complications (therapy), Retrospective Studies (MeSH), Risk Factors (MeSH).
- MESH :
- chemical , metabolism : Creatinine, Hemoglobins.
- chemical , therapeutic use : Angiotensin-Converting Enzyme Inhibitors, Erythropoietin, Immunosuppressive Agents.
- adverse effects : Kidney Transplantation.
- blood : Anemia.
- complications : Kidney Failure, Chronic.
- drug therapy : Anemia.
- epidemiology : Anemia, Cardiovascular Diseases.
- immunology : Kidney Transplantation.
- physiology : Kidney Transplantation.
- surgery : Kidney Failure, Chronic.
- therapy : Postoperative Complications.
- Adult, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors.
Abstract
OBJECTIVE
The CREATE and CHOIR studies showed a higher risk for cardiovascular events associated with hemoglobin (Hb) values >13 g/dL in patients with stage 3-4 chronic kidney disease. In 2007, a stricter policy on the use of erythropoietin (EPO) was adopted at our center, with an Hb target of 11 to 12 g/dL and withdrawal or reduction of EPO when Hb was >12.5 to 13 g/dL. This study was designed to evaluate this new approach.
MATERIALS AND METHODS
The study included patients under follow-up at the transplant outpatient clinic on December 31, 2006 (n = 725), and December 31, 2007 (n = 768). Data were compared between the study populations concerning renal function, Hb, use of EPO, and associated costs.
RESULTS
No significant differences in creatinine or Hb values were observed between the 2 groups (1.47 +/- 0.6 vs 1.42 +/- 0.9 mg/dL and 13.7 +/- 1.5 vs 13.7 +/- 1.6 g/dL, respectively). After implementation of the new protocol, the frequency of severe anemia (Hb <11 g/dL) increased (2% vs 4%; P = .10), the use of EPO decreased (22.1% vs 17.2%; P = .017), and the mean Hb of EPO-treated patients decreased (12.5 +/- 1.4 vs 11.9 +/- 1.0; P < .001). The Hb target (11-12 g/dL) was met in fewer than one third of patients, with no significant differences between the 2 study times.
CONCLUSIONS
A strict policy on EPO application reduces its use and the rate of patients with "excessive" Hb values (which are associated with increased cardiovascular risks), with an acceptable slight increase in severe anemia cases.
DOI: 10.1016/j.transproceed.2008.08.084
PubMed: 19010146
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of anemia in renal transplantation: impact of a stricter application of hemoglobin targets.</title><author><name sortKey="Gentil, M A" sort="Gentil, M A" uniqKey="Gentil M" first="M A" last="Gentil">M A Gentil</name><affiliation wicri:level="1"><nlm:affiliation>Nephrology Unit, Hospital Virgen del Rocío, Seville, Spain. mgentil@cica.es</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Nephrology Unit, Hospital Virgen del Rocío, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation></author><author><name sortKey="Perez Valdivia, M A" sort="Perez Valdivia, M A" uniqKey="Perez Valdivia M" first="M A" last="Pérez-Valdivia">M A Pérez-Valdivia</name></author><author><name sortKey="Gonzalez Roncero, F M" sort="Gonzalez Roncero, F M" uniqKey="Gonzalez Roncero F" first="F M" last="González-Roncero">F M González-Roncero</name></author><author><name sortKey="L Pez Mendoza, M" sort="L Pez Mendoza, M" uniqKey="L Pez Mendoza M" first="M" last="L Pez-Mendoza">M. L Pez-Mendoza</name></author><author><name sortKey="Cabello, V" sort="Cabello, V" uniqKey="Cabello V" first="V" last="Cabello">V. Cabello</name></author><author><name sortKey="Bernal, G" sort="Bernal, G" uniqKey="Bernal G" first="G" last="Bernal">G. Bernal</name></author><author><name sortKey="Su Er, M" sort="Su Er, M" uniqKey="Su Er M" first="M" last="Su Er">M. Su Er</name></author><author><name sortKey="Pereira, P" sort="Pereira, P" uniqKey="Pereira P" first="P" last="Pereira">P. Pereira</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:19010146</idno><idno type="pmid">19010146</idno><idno type="doi">10.1016/j.transproceed.2008.08.084</idno><idno type="wicri:Area/Main/Corpus">000211</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000211</idno><idno type="wicri:Area/Main/Curation">000208</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000208</idno><idno type="wicri:Area/Main/Exploration">000208</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment of anemia in renal transplantation: impact of a stricter application of hemoglobin targets.</title><author><name sortKey="Gentil, M A" sort="Gentil, M A" uniqKey="Gentil M" first="M A" last="Gentil">M A Gentil</name><affiliation wicri:level="1"><nlm:affiliation>Nephrology Unit, Hospital Virgen del Rocío, Seville, Spain. mgentil@cica.es</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Nephrology Unit, Hospital Virgen del Rocío, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation></author><author><name sortKey="Perez Valdivia, M A" sort="Perez Valdivia, M A" uniqKey="Perez Valdivia M" first="M A" last="Pérez-Valdivia">M A Pérez-Valdivia</name></author><author><name sortKey="Gonzalez Roncero, F M" sort="Gonzalez Roncero, F M" uniqKey="Gonzalez Roncero F" first="F M" last="González-Roncero">F M González-Roncero</name></author><author><name sortKey="L Pez Mendoza, M" sort="L Pez Mendoza, M" uniqKey="L Pez Mendoza M" first="M" last="L Pez-Mendoza">M. L Pez-Mendoza</name></author><author><name sortKey="Cabello, V" sort="Cabello, V" uniqKey="Cabello V" first="V" last="Cabello">V. Cabello</name></author><author><name sortKey="Bernal, G" sort="Bernal, G" uniqKey="Bernal G" first="G" last="Bernal">G. Bernal</name></author><author><name sortKey="Su Er, M" sort="Su Er, M" uniqKey="Su Er M" first="M" last="Su Er">M. Su Er</name></author><author><name sortKey="Pereira, P" sort="Pereira, P" uniqKey="Pereira P" first="P" last="Pereira">P. Pereira</name></author></analytic><series><title level="j">Transplantation proceedings</title><idno type="ISSN">0041-1345</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Anemia (blood)</term><term>Anemia (drug therapy)</term><term>Anemia (epidemiology)</term><term>Angiotensin-Converting Enzyme Inhibitors (therapeutic use)</term><term>Cardiovascular Diseases (epidemiology)</term><term>Creatinine (metabolism)</term><term>Drug Administration Schedule (MeSH)</term><term>Erythropoietin (therapeutic use)</term><term>Female (MeSH)</term><term>Hemoglobins (metabolism)</term><term>Humans (MeSH)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Kidney Failure, Chronic (complications)</term><term>Kidney Failure, Chronic (surgery)</term><term>Kidney Transplantation (adverse effects)</term><term>Kidney Transplantation (immunology)</term><term>Kidney Transplantation (physiology)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Postoperative Complications (therapy)</term><term>Retrospective Studies (MeSH)</term><term>Risk Factors (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Anémie (sang)</term><term>Anémie (traitement médicamenteux)</term><term>Anémie (épidémiologie)</term><term>Calendrier d'administration des médicaments (MeSH)</term><term>Complications postopératoires (thérapie)</term><term>Créatinine (métabolisme)</term><term>Défaillance rénale chronique (chirurgie)</term><term>Défaillance rénale chronique (complications)</term><term>Facteurs de risque (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Hémoglobines (métabolisme)</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (usage thérapeutique)</term><term>Maladies cardiovasculaires (épidémiologie)</term><term>Mâle (MeSH)</term><term>Transplantation rénale (effets indésirables)</term><term>Transplantation rénale (immunologie)</term><term>Transplantation rénale (physiologie)</term><term>Érythropoïétine (usage thérapeutique)</term><term>Études rétrospectives (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Creatinine</term><term>Hemoglobins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiotensin-Converting Enzyme Inhibitors</term><term>Erythropoietin</term><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Kidney Transplantation</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Anemia</term></keywords><keywords scheme="MESH" qualifier="chirurgie" xml:lang="fr"><term>Défaillance rénale chronique</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Kidney Failure, Chronic</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Anemia</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Défaillance rénale chronique</term><term>Transplantation rénale</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Anemia</term><term>Cardiovascular Diseases</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Transplantation rénale</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Kidney Transplantation</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Créatinine</term><term>Hémoglobines</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Transplantation rénale</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Kidney Transplantation</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anémie</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Kidney Failure, Chronic</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Postoperative Complications</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Complications postopératoires</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Anémie</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Immunosuppresseurs</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term><term>Érythropoïétine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Anémie</term><term>Maladies cardiovasculaires</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Risk Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Calendrier d'administration des médicaments</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>The CREATE and CHOIR studies showed a higher risk for cardiovascular events associated with hemoglobin (Hb) values >13 g/dL in patients with stage 3-4 chronic kidney disease. In 2007, a stricter policy on the use of erythropoietin (EPO) was adopted at our center, with an Hb target of 11 to 12 g/dL and withdrawal or reduction of EPO when Hb was >12.5 to 13 g/dL. This study was designed to evaluate this new approach.</p></div><div type="abstract" xml:lang="en"><p><b>MATERIALS AND METHODS</b></p><p>The study included patients under follow-up at the transplant outpatient clinic on December 31, 2006 (n = 725), and December 31, 2007 (n = 768). Data were compared between the study populations concerning renal function, Hb, use of EPO, and associated costs.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>No significant differences in creatinine or Hb values were observed between the 2 groups (1.47 +/- 0.6 vs 1.42 +/- 0.9 mg/dL and 13.7 +/- 1.5 vs 13.7 +/- 1.6 g/dL, respectively). After implementation of the new protocol, the frequency of severe anemia (Hb <11 g/dL) increased (2% vs 4%; P = .10), the use of EPO decreased (22.1% vs 17.2%; P = .017), and the mean Hb of EPO-treated patients decreased (12.5 +/- 1.4 vs 11.9 +/- 1.0; P < .001). The Hb target (11-12 g/dL) was met in fewer than one third of patients, with no significant differences between the 2 study times.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>A strict policy on EPO application reduces its use and the rate of patients with "excessive" Hb values (which are associated with increased cardiovascular risks), with an acceptable slight increase in severe anemia cases.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19010146</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0041-1345</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>9</Issue><PubDate><Year>2008</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Transplantation proceedings</Title></Journal><ArticleTitle>Treatment of anemia in renal transplantation: impact of a stricter application of hemoglobin targets.</ArticleTitle><Pagination><MedlinePgn>2916-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.transproceed.2008.08.084</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The CREATE and CHOIR studies showed a higher risk for cardiovascular events associated with hemoglobin (Hb) values >13 g/dL in patients with stage 3-4 chronic kidney disease. In 2007, a stricter policy on the use of erythropoietin (EPO) was adopted at our center, with an Hb target of 11 to 12 g/dL and withdrawal or reduction of EPO when Hb was >12.5 to 13 g/dL. This study was designed to evaluate this new approach.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The study included patients under follow-up at the transplant outpatient clinic on December 31, 2006 (n = 725), and December 31, 2007 (n = 768). Data were compared between the study populations concerning renal function, Hb, use of EPO, and associated costs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No significant differences in creatinine or Hb values were observed between the 2 groups (1.47 +/- 0.6 vs 1.42 +/- 0.9 mg/dL and 13.7 +/- 1.5 vs 13.7 +/- 1.6 g/dL, respectively). After implementation of the new protocol, the frequency of severe anemia (Hb <11 g/dL) increased (2% vs 4%; P = .10), the use of EPO decreased (22.1% vs 17.2%; P = .017), and the mean Hb of EPO-treated patients decreased (12.5 +/- 1.4 vs 11.9 +/- 1.0; P < .001). The Hb target (11-12 g/dL) was met in fewer than one third of patients, with no significant differences between the 2 study times.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A strict policy on EPO application reduces its use and the rate of patients with "excessive" Hb values (which are associated with increased cardiovascular risks), with an acceptable slight increase in severe anemia cases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gentil</LastName><ForeName>M A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Nephrology Unit, Hospital Virgen del Rocío, Seville, Spain. mgentil@cica.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pérez-Valdivia</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>González-Roncero</LastName><ForeName>F M</ForeName><Initials>FM</Initials></Author><Author ValidYN="Y"><LastName>López-Mendoza</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cabello</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Bernal</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Suñer</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transplant Proc</MedlineTA><NlmUniqueID>0243532</NlmUniqueID><ISSNLinking>0041-1345</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>11096-26-7</RegistryNumber><NameOfSubstance UI="D004921">Erythropoietin</NameOfSubstance></Chemical><Chemical><RegistryNumber>AYI8EX34EU</RegistryNumber><NameOfSubstance UI="D003404">Creatinine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000740" MajorTopicYN="N">Anemia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003404" MajorTopicYN="N">Creatinine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004921" MajorTopicYN="N">Erythropoietin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="N">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="N">Kidney Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19010146</ArticleId><ArticleId IdType="pii">S0041-1345(08)01162-7</ArticleId><ArticleId IdType="doi">10.1016/j.transproceed.2008.08.084</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country></list><tree><noCountry><name sortKey="Bernal, G" sort="Bernal, G" uniqKey="Bernal G" first="G" last="Bernal">G. Bernal</name><name sortKey="Cabello, V" sort="Cabello, V" uniqKey="Cabello V" first="V" last="Cabello">V. Cabello</name><name sortKey="Gonzalez Roncero, F M" sort="Gonzalez Roncero, F M" uniqKey="Gonzalez Roncero F" first="F M" last="González-Roncero">F M González-Roncero</name><name sortKey="L Pez Mendoza, M" sort="L Pez Mendoza, M" uniqKey="L Pez Mendoza M" first="M" last="L Pez-Mendoza">M. L Pez-Mendoza</name><name sortKey="Pereira, P" sort="Pereira, P" uniqKey="Pereira P" first="P" last="Pereira">P. Pereira</name><name sortKey="Perez Valdivia, M A" sort="Perez Valdivia, M A" uniqKey="Perez Valdivia M" first="M A" last="Pérez-Valdivia">M A Pérez-Valdivia</name><name sortKey="Su Er, M" sort="Su Er, M" uniqKey="Su Er M" first="M" last="Su Er">M. Su Er</name></noCountry><country name="Espagne"><noRegion><name sortKey="Gentil, M A" sort="Gentil, M A" uniqKey="Gentil M" first="M A" last="Gentil">M A Gentil</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SanteChoraleV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000211 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000211 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SanteChoraleV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19010146
|texte= Treatment of anemia in renal transplantation: impact of a stricter application of hemoglobin targets.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19010146" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SanteChoraleV4
| This area was generated with Dilib version V0.6.37. |  |